Series Seed (SANE Edition): The Goldilocks Financing for Seed-Stage Startups

If you've raised a seed round recently, you've probably confronted an uncomfortable choice: use a SAFE and defer all the decisions that matter, or negotiate a full NVCA equity round and spend a month and $50K+ in legal fees while you're still confirming product-market fit.

For a lot of companies, neither is the right answer.

The SAFE is a brilliant instrument for what it was designed to do — fast, lightweight pre-seed checks where pricing is premature. And the NVCA suite is the gold standard for Series A and beyond, where the stakes justify the overhead. But there's a large population of seed-stage companies caught in the middle: ready for real equity, a clean cap table, and a functional board, but not ready to negotiate registration rights and IPO demand thresholds.

That's who the Series Seed was built for. And after years of languishing without updates, we think it deserves a revival.

We're releasing the Series Seed (SANE Edition) — an updated, modernized fork of the original Series Seed documents, aligned with the October 2025 NVCA model document revisions. It's open source, free to use, and designed for companies in the middle.

---

A brief history

The Series Seed documents were originally developed by Ted Wang at Fenwick & West as a lightweight alternative to the full NVCA suite for seed-stage financings. They were elegant: a term sheet, an investment agreement, and a certificate of incorporation. Three documents instead of five. Real preferred stock, a real board, real investor rights — without the hundred-page overhead.

But the documents haven't been materially updated since v3.2, and the market has moved. The NVCA released significant model document revisions in October 2025. National security compliance requirements have changed. QSBS rules have evolved. Drafting conventions have modernized. The original Series Seed needed a refresh to remain viable — so we built one.

Why not just use a SAFE?

SAFEs work. For early pre-seed checks where pricing is genuinely premature, they're still the right tool. But we regularly see companies raising $1M, $2M, even $3M+ on stacked SAFEs when a priced seed round would serve everyone better.

If you've raised on SAFEs — especially multiple SAFEs at different valuation caps — you know the friction that accumulates. The SANE edition is for you.

Why founders should care

Cap table certainty. While SAFEs are outstanding, nobody — including you — knows exactly who owns what. Dilution modeling becomes guesswork. Pro rata rights are theoretical. The post-money SAFE was supposed to fix this, but it introduced its own complications. With priced equity, the cap table is clean and final at closing. You know your number.

A functional board. SAFEs defer governance entirely. That might sound like freedom, but it also means no formal board, no designated seats, and no structured accountability. For companies past the napkin-sketch stage, an engaged board with founder and investor seats creates strategic value — not just oversight. You get advisors who are contractually in the room, not just on a text thread.

No conversion surprises. SAFE stacking at different valuation caps creates a web of contingent economics that only resolves at the next priced round. Founders routinely get surprised by how much dilution materializes when the SAFEs convert — not because the terms were bad, but because the interaction effects were invisible. A priced seed round eliminates the conversion event entirely. What you negotiate is what you get.

Series A readiness. Clean preferred stock on NVCA-aligned documents means your Series A starts from solid footing. Your next-round counsel can redline the SANE certificate against the NVCA model certificate and immediately see the delta — no archaeology, no unwinding a non-standard structure.

Why investors should care

Better tax treatment. SAFE holders arguably don't start the clock on qualified small business stock (QSBS) treatment until conversion — a point the IRS hasn't definitively resolved, and one that matters a lot for investors planning to hold through a significant exit. Preferred stock purchased at a priced round starts the QSBS clock at closing. For investors targeting the Section 1202 exclusion, that timing difference can be worth millions.

Cap table certainty cuts both ways. Investors with SAFEs outstanding can't cleanly calculate their ownership percentage, their liquidation waterfall position, or their effective pro rata. With priced equity, every investor knows exactly what they own and exactly where they stand.

Board representation and protective provisions. SAFEs give investors no governance rights. No board seat, no protective provisions, no consent rights over actions that could harm their investment. The SANE Investment Agreement provides all of these — designated board seats, information rights, pro rata participation in future rounds, and protective provisions that require investor consent for the things that matter (issuing senior stock, changing the charter, taking on debt beyond agreed thresholds, etc.).

What's in the box

SANE stands for Simple Agreement for Now Equity — a deliberate nod to the instrument it's designed to complement.

The entire suite is three core documents:

1. Term Sheet — Non-binding summary of principal deal terms.
2. Investment Agreement — A single binding document covering purchase mechanics, representations, information rights, participation rights, voting, and general provisions. It consolidates what the NVCA spreads across four separate agreements.
3. Certificate of Incorporation — Restated Delaware charter defining stock rights, conversion mechanics, liquidation preferences, and protective provisions.

Plus ancillary closing documents (Board Consent, Stockholder Consent, Investor Questionnaire) and a Variable Reference Map that tracks every fill-in variable across documents.

Three documents. A closing timeline measured in days. Legal costs closer to a SAFE round than a Series A.

Built as an NVCA on-ramp

One of the core design goals was making the transition to a full NVCA suite at Series A as frictionless as possible.

The Certificate of Incorporation tracks the NVCA model certificate section-for-section. The Investment Agreement includes an MFN clause (Section 4.2) that explicitly contemplates the transition — seed investors' rights get amended and restated into the next financing's full NVCA document suite. Your Series A lawyers aren't unwinding a non-standard structure; they're upgrading a familiar one.

What we updated

The original Series Seed documents hadn't been updated in years. The NVCA released significant model document revisions in October 2025. We incorporated the updates that matter at seed stage and intentionally left out the ones that don't.

Included:

• National security compliance — Basic OFAC/sanctions reps and foreign person monitoring (full OISP/DSP framework deferred to Series A)
• QSBS eligibility covenant — Company covenant to maintain QSBS eligibility
• Board designation non-transferability — Matching the new NVCA default
• Restricted Person definitions — Sanctions-excluded persons can't participate in governance votes
• Rule 506(d) bad actor representations — For both the company and purchaser board designees

Intentionally excluded:

• Tranched financing mechanics (inappropriate complexity at seed)
• Governance policy suites (Series A+ requirement)
• S-1 demand registration minimums (no registration rights at seed)
• Severance caps (addressed at Series A)

Other improvements:

• Modernized "Future Rights" to "Most Favored Nation" with explicit scope
• Added convertible securities consent mechanism for SAFE and note conversions at closing
• Replaced "best efforts" with "reasonable efforts" throughout
• Drafting modernization based on Adams, A Manual of Style for Contract Drafting (4th ed.)

When to use SANE

This isn't a SAFE replacement. SAFEs remain the right tool when pricing is genuinely premature, the check is small, and governance can wait.

SANE is the right fit when you're in the middle — and a lot of companies are:

• You're raising $1M+ and your investors expect governance rights
• You want cap table certainty, not conversion math you'll reconcile later
• You want a board that functions as a board
• QSBS timing matters to your investors
• You've already done a SAFE round and you're ready for something more substantial
• You want Series A readiness without Series A overhead

Open source, free to use

The entire document suite is on GitHub. Markdown source, Word downloads, a variable reference map, and all ancillary closing documents. Fork it, use it, submit a PR if you find something to improve.

If you want help putting it to work — or you're deciding whether a SAFE, SANE, or full NVCA round is the right structure for your raise — book a call. That's what we're here for.

---

The Series Seed documents were originally developed by Ted Wang at Fenwick & West. The SANE Edition is a modernized fork of Series Seed v3.2, with select provisions adapted from the Cooley LLP fork, updated by Rubicon Law and aligned with the October 2, 2025 NVCA model document release.